
-
'Frightening': US restaurants, producers face tariff whiplash
-
Cuba looks to sun to solve its energy crisis
-
Experts warn 'AI-written' paper is latest spin on climate change denial
-
PSG eye becoming France's first 'Invincibles'
-
Late birdie burst lifts Ryder to Texas Open lead
-
Five potential Grand National fairytale endings
-
Trump purges national security team after meeting conspiracist
-
More work for McIlroy even with two wins before Masters
-
Trump hopeful of 'great' PGA-LIV golf merger
-
No.1 Scheffler goes for third Masters crown in four years
-
Where Trump's tariffs could hurt Americans' wallets
-
Trump says 'very close to a deal' on TikTok
-
Trump tariffs on Mexico: the good, the bad, the unknown
-
Postecoglou denies taunting Spurs fans in Chelsea defeat
-
Oscar-winning Palestinian director speaks at UN on Israeli settlements
-
With tariff war, Trump also reshapes how US treats allies
-
Fernandez fires Chelsea into fourth as pressure mounts on Postecoglou
-
South Korea court to decide impeached president's fate
-
Penguin memes take flight after Trump tariffs remote island
-
E.T., no home: Original model of movie alien doesn't sell at auction
-
Italy's Brignone has surgery on broken leg with Winter Olympics looming
-
Trump defiant as tariffs send world markets into panic
-
City officials vote to repair roof on home of MLB Rays
-
Rockets forward Brooks gets one-game NBA ban for technicals
-
Pentagon watchdog to probe defense chief over Signal chat row
-
US tariffs could push up inflation, slow growth: Fed official
-
New Bruce Springsteen music set for June 27 release
-
Tom Cruise pays tribute to Val Kilmer
-
Mexico president welcomes being left off Trump's tariffs list
-
Zuckerberg repeats Trump visits in bid to settle antitrust case
-
US fencer disqualified for not facing transgender rival
-
'Everyone worried' by Trump tariffs in France's champagne region
-
Italy's Brignone suffers broken leg with Winter Olympics looming
-
Iyer blitz powers Kolkata to big IPL win over Hyderabad
-
Russian soprano Netrebko to return to London's Royal Opera House
-
French creche worker gets 25 years for killing baby with drain cleaner
-
UK avoids worst US tariffs post-Brexit, but no celebrations
-
Canada imposing 25% tariff on some US auto imports
-
Ruud wants 'fair share' of Grand Slam revenue for players
-
Lesotho, Africa's 'kingdom in the sky' jolted by Trump
-
Trump's trade math baffles economists
-
Gaza heritage and destruction on display in Paris
-
'Unprecedented crisis' in Africa healthcare: report
-
Pogacar gunning for blood and thunder in Tour of Flanders
-
Macron calls for suspension of investment in US until tariffs clarified
-
Wall St leads rout as world reels from Trump tariffs
-
Mullins gets perfect National boost with remarkable four-timer
-
Trump tariffs hammer global stocks, dollar and oil
-
Authors hold London protest against Meta for 'stealing' work to train AI
-
Tate Modern gifted 'extraordinary' work by US artist Joan Mitchell

US drugmaker Eli Lilly says slashing insulin prices
US pharmaceutical giant Eli Lilly announced Wednesday it would cut the cost of its insulin by 70 percent, with President Joe Biden calling on others to follow suit to tackle soaring drug prices.
Manufacturers have ratcheted up insulin prices in recent years, hitting millions of Americans living with diabetes -- and drawing sharp political criticism.
"Insulin costs less than $10 to make, but Americans are sometimes forced to pay over $300 for it. It's flat wrong," said Biden, hailing Eli Lilly's price cut as "huge news."
"It's time for other manufacturers to follow," he added.
Indianapolis-based Lilly announced a series of steps to rein in prices of the life-saving drug, such as capping out-of-pocket costs at $35 per month for people with insurance.
"Lilly is taking these actions to make it easier to access Lilly insulin and help Americans who may have difficulty navigating a complex healthcare system," the drugmaker said in a statement.
While the $35 cap takes effect immediately, other measures will be implemented in the course of 2023.
A centerpiece is the 70 percent price drop in Humalog, Lilly's most commonly prescribed insulin.
The incidence of diabetes in the United States in adults has doubled over the last 20 years, afflicting 37.3 million people, according to the US Centers for Disease Control and Prevention.
Insulin prices have soared in the US, costing over eight times more than in 32 comparable high-income countries, a 2020 Rand Corporation study found.
The unaffordability of insulin -- particularly to uninsured Americans -- has become a rallying cry for pharmaceutical industry critics.
- Self-rationing insulin -
The cost of a five-pack of Humalog is currently $530.40, although the out-of-pocket price to a user varies depending on one's insurance plan. An average monthly use varies by user, Eli Lilly says on its website.
Drug pricing in the United States is affected not only by the cost of producing and distributing the pharmaceutical, but also other players such as insurers and pharmacy benefit management companies.
Critics such as progressive Senator Bernie Sanders have blasted the industry as emblematic of "unacceptable corporate greed."
"At a time when Eli Lilly made over $7 billion in profits last year, public pressure forced them to reduce the price of insulin by 70%," Sanders said Wednesday after the price-cut announcement.
"Sanofi and Novo Nordisk must do the same," he added, referring to two other companies which along with Lilly dominate the insulin market.
A survey by nonprofit T1International showed that one in four respondents living with diabetes reported rationing their insulin because of the financial strain.
The Inflation Reduction Act, signed into law last year by Biden, capped insulin prices for Medicare recipients at $35 per month, but people with private insurance or without insurance were left out.
Biden, in his State of the Union Address, called on lawmakers to rein in "Big Pharma" and "finish the job this time" by instituting a national cap on insulin.
In the company's statement, Eli Lilly Chief Executive David Ricks called on rival producers to join the effort.
"We know that 7 out of 10 Americans don't use Lilly insulin. We are calling on policymakers, employers and others to join us in making insulin more affordable," said Ricks.
"While the current healthcare system provides access to insulin for most people with diabetes, it still does not provide affordable insulin for everyone and that needs to change."
The company's statement referred uninsured consumers to an insulin affordability website, saying they could "receive Lilly insulins for $35 per month."
P.Stevenson--AMWN